CN113474007A - 缀合物 - Google Patents

缀合物 Download PDF

Info

Publication number
CN113474007A
CN113474007A CN201980092600.6A CN201980092600A CN113474007A CN 113474007 A CN113474007 A CN 113474007A CN 201980092600 A CN201980092600 A CN 201980092600A CN 113474007 A CN113474007 A CN 113474007A
Authority
CN
China
Prior art keywords
conjugate
alkyl
group
hydrogen
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980092600.6A
Other languages
English (en)
Chinese (zh)
Inventor
A·L·斯韦尔
E·S·尼根达
S·N·奥伯恩
R·洛佩斯-冈萨雷斯
R·马克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transfont Holdings Ltd
Original Assignee
Transfont Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transfont Holdings Ltd filed Critical Transfont Holdings Ltd
Publication of CN113474007A publication Critical patent/CN113474007A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CN201980092600.6A 2018-12-18 2019-12-18 缀合物 Pending CN113474007A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1820626.8 2018-12-18
GBGB1820626.8A GB201820626D0 (en) 2018-12-18 2018-12-18 Conjugates
PCT/EP2019/086120 WO2020127602A1 (en) 2018-12-18 2019-12-18 Conjugates

Publications (1)

Publication Number Publication Date
CN113474007A true CN113474007A (zh) 2021-10-01

Family

ID=65147114

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980092600.6A Pending CN113474007A (zh) 2018-12-18 2019-12-18 缀合物

Country Status (11)

Country Link
US (1) US20220054658A1 (cg-RX-API-DMAC7.html)
EP (1) EP3897737A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022514335A (cg-RX-API-DMAC7.html)
KR (1) KR20210106496A (cg-RX-API-DMAC7.html)
CN (1) CN113474007A (cg-RX-API-DMAC7.html)
AU (1) AU2019400788A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021011860A2 (cg-RX-API-DMAC7.html)
CA (1) CA3123960A1 (cg-RX-API-DMAC7.html)
GB (1) GB201820626D0 (cg-RX-API-DMAC7.html)
MX (1) MX2021006802A (cg-RX-API-DMAC7.html)
WO (1) WO2020127602A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114685430A (zh) * 2022-03-18 2022-07-01 浙江大学 芬苯达唑类似物及制备方法和应用
CN120987848A (zh) * 2025-07-10 2025-11-21 广州大学 一种含胍基结构单元的ε-己内酰胺化合物及其制备方法和应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024049306A1 (en) * 2022-08-31 2024-03-07 Lopez Gonzalez Ricardo Chemical conjugates, compositions, and methods of preparation and use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102395565A (zh) * 2008-12-05 2012-03-28 俄勒冈健康科学大学 具有抗寄生物活性和抗感染活性的化合物
CN103261169A (zh) * 2010-09-24 2013-08-21 密歇根大学董事会 脱泛素酶抑制剂及其应用方法
US20130345270A1 (en) * 2010-11-12 2013-12-26 Waake Forest University Health Sciences Methods of treating cancer and other disorders
US20140038914A1 (en) * 2011-01-18 2014-02-06 The Royal Institution For The Advancement Of Learning/Mcgill University Compounds for use in the treatment of bacterial infection
CN107257793A (zh) * 2015-01-20 2017-10-17 梅里亚股份有限公司 抗蠕虫化合物、组合物及其使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068485B1 (en) 1981-07-01 1987-11-11 Sanraku Incorporated Novel antibiotics and process for production thereof
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2019060634A1 (en) 2017-09-20 2019-03-28 Thiogenesis Therapeutics, Inc. METHODS OF TREATING CYSTEAMINE SENSITIVE DISORDERS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102395565A (zh) * 2008-12-05 2012-03-28 俄勒冈健康科学大学 具有抗寄生物活性和抗感染活性的化合物
CN103261169A (zh) * 2010-09-24 2013-08-21 密歇根大学董事会 脱泛素酶抑制剂及其应用方法
US20130345270A1 (en) * 2010-11-12 2013-12-26 Waake Forest University Health Sciences Methods of treating cancer and other disorders
US20140038914A1 (en) * 2011-01-18 2014-02-06 The Royal Institution For The Advancement Of Learning/Mcgill University Compounds for use in the treatment of bacterial infection
CN107257793A (zh) * 2015-01-20 2017-10-17 梅里亚股份有限公司 抗蠕虫化合物、组合物及其使用方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ALAN L. SEWELL等: "Fast and Flexible Synthesis of Pantothenic Acid and CJ-15, 801", ORGANIC LETTERS, vol. 13, no. 4, 20 January 2011 (2011-01-20), pages 800 - 803, XP055052154, DOI: 10.1021/ol103114w *
CHONG HAN, RUICHAO SHEN, SHUN SU, AND JOHN A. PORCO: "Copper-Mediated Synthesis of N-Acyl Vinylogous Carbamic Acids and Derivatives: Synthesis of the Antibiotic CJ-15, 8011-61", ORGANIC LETTERS, vol. 6, no. 1, 11 December 2003 (2003-12-11), pages 27 - 30, XP055052152, DOI: 10.1021/ol0360041 *
CHRISTINA SPRY等: "Structure-activity analysis of CJ-15, 801 analogues that interact with Plasmodium falciparum pantothenate kinase and inhibit parasite proliferation", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 143, 1 January 2018 (2018-01-01), pages 1139 - 1147 *
LINDY HOLDEN-DYE, ROBERT J WALKER: "Anthelmintic drugs and nematicides: studies in Caenorhabditis elegans", WORMBOOK, 16 December 2014 (2014-12-16), pages 1 - 29, XP055478099, DOI: 10.1895/wormbook.1.143.2 *
宋军科;才学鹏;骆学农;林青;窦永喜;于三科;: "寄生虫半胱氨酸蛋白酶研究进展", 动物医学进展, no. 12, 20 December 2011 (2011-12-20) *
邱宗文: "寄生虫的半胱氨酸蛋白酶", 国外医学.寄生虫病分册, no. 4, 15 August 2003 (2003-08-15) *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114685430A (zh) * 2022-03-18 2022-07-01 浙江大学 芬苯达唑类似物及制备方法和应用
CN120987848A (zh) * 2025-07-10 2025-11-21 广州大学 一种含胍基结构单元的ε-己内酰胺化合物及其制备方法和应用
CN120987848B (zh) * 2025-07-10 2026-07-21 广州大学 一种含胍基结构单元的ε-己内酰胺化合物及其制备方法和应用

Also Published As

Publication number Publication date
GB201820626D0 (en) 2019-01-30
KR20210106496A (ko) 2021-08-30
JP2025072404A (ja) 2025-05-09
JP2022514335A (ja) 2022-02-10
US20220054658A1 (en) 2022-02-24
WO2020127602A1 (en) 2020-06-25
EP3897737A1 (en) 2021-10-27
CA3123960A1 (en) 2020-06-25
MX2021006802A (es) 2021-08-16
AU2019400788A1 (en) 2021-08-12
BR112021011860A2 (pt) 2021-09-08

Similar Documents

Publication Publication Date Title
JP2025072404A (ja) コンジュゲート
JP6419990B2 (ja) ブロモドメイン阻害剤としてのベンゾイミダゾール誘導体
JPH10508613A (ja) 内部寄生虫を駆除するためのジオキソモルホリンの使用、新規ジオキソモルホリンおよびそれらの製造方法
WO1982001873A1 (en) 1-sulfo-2-oxoazetidine derivatives and process for their preparation
TW201402537A (zh) 犬尿胺酸-3-單氧化酶抑制劑,其醫藥組成物及使用方法
CH647757A5 (fr) Derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee.
TW202342492A (zh) 用於治療癌症之基於硫鏈絲菌肽之化合物及其製備
EA013244B1 (ru) 8-МЕТОКСИ-9Н-ИЗОТИАЗОЛО[5,4-b]ХИНОЛИН-3,4-ДИОНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ПРОТИВОИНФЕКЦИОННЫХ СРЕДСТВ
CN108137599B (zh) 化合物
JP7696301B2 (ja) タンパク質分解のための化合物、組成物、および方法
JP2025524721A (ja) メタロトーシス関連障害の処置において使用するためのセロトニン類似体
KR20240145010A (ko) Klf2 유도제 및 이의 사용 방법
TW202525320A (zh) 用於處置或預防中樞神經系損傷疾病的環狀胜肽衍生物組成物
EP2417151B1 (fr) Peptides cycliques à activité antiparasitaire
CN1257072A (zh) 新的1,2-二硫戊环化合物、其制备方法及包含它们的药物组合物
US20050203180A1 (en) Cinnamic acid dimers, their preparation and the use thereof for treating neurodegenerative disease
BE1007544A3 (fr) Derives de thioalkylthiocarbacephalosporines.
US8058468B2 (en) Carbamate antibiotics
OA13294A (fr) Molécules duales contenant un dérivé peroxydique, leur synthèse et leurs applications thérapeutiques.
US20200079750A1 (en) Compound or salt thereof, antiviral agent, and pharmaceutical composition
Karmakar et al. Evaluating the leishmanicidal activity of m-Nitrocinnamic acid containing lipophilic peptide against leishmania donovani
WO2012116577A1 (zh) 绿原酸类似物及其制备方法和应用
US20080280964A1 (en) Novel Antibiotics Comprising Bis(1-Aryl-5-Tetrazolyl)Methane Derivatives
NL8101439A (nl) Aminozuurverbindingen en bereiding en hun gebruik als farmaceutisch preparaat.
HK40111688A (en) Inducers of klf2 and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211001